Introduction
============

Current HIV incidence rates in highly impacted regions reflect the magnitude of the epidemic and point out an apparent lack of HIV prevention methods, specifically for women. Sixty-eight percent of the 2.3 million adults newly infected with HlV in 2008 live in sub-Saharan Africa, where approximately 60% of infected individuals are women \[[@B1]\]. Women and adolescent girls are especially vulnerable to HIV infection in sub-Saharan Africa not only because of their increased physiological susceptibility to heterosexual transmission, but also because of social, legal, and economic disadvantages \[[@B1]\]. According to the most recent estimate, the number of people living with HIV is 33.4 million \[[@B1]\]. In the nine countries in southern Africa affected most by HIV (Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, Zambia, and Zimbabwe), prevalence among young women aged 15-24 years was reported to be approximately 3 times higher than among men of the same age \[[@B2]\]. HIV prevention options for women are presently limited in this setting.

Microbicides to prevent HIV infection in women are vaginally applied topical products that interfere with HIV infection at one or more steps in the replication cycle. This paper summarizes research to date on early generation product development efforts (polyanions, surfactants, acidifying agents) and next generation antiretroviral (ARV)-based HIV microbicides and introduces the concept of pre-exposure prophylaxis (PrEP) for the prevention of HIV transmission.

The Need for a Female-Initiated HIV Prevention Method
=====================================================

Half of the exposed population currently has no effective means of self-initiated HIV prevention; and although condoms provide good protection from HIV infection, their regular use is not always negotiable by women. The effectiveness of an HIV prevention method is impacted by its correct and consistent use. Therefore, microbicide research and development has also focused on the topic of adherence, and factors affecting adherence, such as preferred dosage forms and regimens, stigma associated with microbicide use, male perception of microbicide use, and various dosage forms and regimens.

An ideal microbicide product would be highly effective against HIV transmission and potentially other pathogens, have a very good safety profile, create no drug-drug interactions with other vaginal products, and could be easily and discreetly used on a regular basis. The half-life of the active pharmaceutical ingredient ideally would be long enough so that protective drug levels would be maintained in tissues even with lapses in product use. Dosing regimens should accommodate the range in female sexual behavior from regular intercourse to periods of abstinence. Long-acting dosage forms such as vaginal rings may be an attractive feature for women as well as improve adherence and therefore the effectiveness of the product. Product formulations that combine HIV prevention with contraception are in early stages of development and would offer women additional options \[[@B3]\].

Overview of Research and Development Efforts with Non-ARV-Based Microbicides
============================================================================

Several early generation microbicide gels were evaluated for efficacy in phase IIb and phase III trials with disappointing results. These include the surfactants nonoxynol-9 \[[@B4]\] and SAVVY (Cellegy Pharmaceuticals, Huntington Valley, PA, USA) \[[@B5]\]; three polyanions, cellulose sulfate \[[@B6]\], Carraguard^®^(Population Council, New York, NY, USA) \[[@B7]\], and PRO 2000 (Endo Pharmaceuticals, Chadds Ford, PA, USA) \[[@B8]\]; and an acidifying agent, BufferGel (ReProtect LLC, Baltimore, MD, USA) \[[@B8]\]. None proved to inhibit HIV infection, and in fact with three of the gels, nonoxynol-9, cellulose sulfate, and SAVVY, a trend toward increased risk of HIV infection was observed \[[@B4]-[@B6]\].

Overview of Research and Developments Efforts with ARV-Based Microbicides
=========================================================================

Microbicide research has now shifted to development of next-generation, ARV-based formulations in multiple dosage forms such as vaginal gels, rings, films, soft-gel capsules, and tablets \[[@B9]-[@B11]\]. Formulations of ARVs that target reverse transcriptase are furthest along in development as topical microbicides (Table [1](#T1){ref-type="table"}). Proof-of-concept was shown recently with a vaginal gel containing tenofovir, an NRTI.

###### 

ARV-Based Microbicides Products in Development.

  Product                                         MOA                    License Holder(s)    Phase of Development
  ----------------------------------------------- ---------------------- -------------------- ----------------------
  Tenofovir gel                                   NRTI                   CONRAD and IPM       Phase IIB
  Dapivirine gel and ring                         NNRTI                  IPM                  Phase I/II
  Dapivirine-maraviroc combination gel and ring   NNRTI + CCR5 blocker   IPM                  Phase I planned
  Maraviroc ring and gel                          CCR5 blocker           IPM                  Phase I planned
  Maraviroc-tenofovir combination film            CCR5 blocker + NRTI    IPM                  Late preclinical
  MIY-150 gel and ring                            NNRTI                  Population Council   Late preclinical

Tenofovir
---------

In July 2010, positive results were reported from the CAPRISA 004 trial in South Africa \[[@B12]\]. When compared with the HEC-based universal placebo gel, 1% tenofovir gel was 39% effective (incidence rate ratio 0.61, p = 0.017) at reducingg new HIV infection after 30 months of coitally-dependent use by sexually-active women aged 18 to 40 years. The effectiveness increased to 54% (p = 0.025) when only data for women who used the gel correctly were analyzed. The protective effect of tenofovir gel was evident at 6 months, 50% at 12 months (p = 0.007), and was 40% at 24 months (p = 0.013). Tenofovir gel had a favorable safety profile: only diarrhea and gastrointestinal infections were significantly higher in the tenofovir gel vs. placebo gel group (17% vs. 11%, p = 0.02).

An ongoing study (MTN 003, also referred to as the \"Vaginal and Oral Interventions to Control the Epidemic\" or \"VOICE\" trial) funded by NIAID and sponsored by the Microbicide Trials Network is being conducted in Africa (Malawi, South Africa, Uganda, Zimbabwe) to test the effectiveness of daily 1% tenofovir gel vs. placebo gel as well as the effectiveness of oral tenofovir disoproxil fumarate (Viread^®^, Gilead Sciences, Foster City, CA, USA) and oral emtric-itabine/tenofovir disoproxil fumarate (Truvada^®^, Gilead Sciences) vs. oral placebo measured by HIV seroconversion. Extended safety of the products in women at risk for sexually transmitted HIV infection will also be assessed. The results of this study may answer the question whether daily dosing (used in the VOICE trial) improves adherence and effectiveness of tenofovir gel compared with coitally-associated dosing (used in the CAPRISA trial) without compromising the safety profile. The results of the VOICE trial are expected in 2013.

Dapivirine
----------

Dapivirine, an NNRTI initially developed by Tibotec Pharmaceuticals in Belgium, has been tested for safety in sexually active, HIV-negative women in both vaginal gel (daily dosing) and vaginal ring (monthly dosing) formulations. Both dosage forms have been shown to have similar safety profiles to their respective placebos and to release dapivirine into the lower female genital tract at concentrations well above those shown to be protective in vitro and ex vivo, and well above concentrations in plasma that have been shown to reduce viral load \[[@B13]-[@B19]\]. Two more recently developed formulations of 0.05% dapivirine gel have been tested in safety studies in Kenya, Malawi, Rwanda, South Africa, and the United States. A safety study with the current dapivirine ring formulation (25 mg) is ongoing in South Africa, Kenya, and Malawi, and two pharmaco-kinetics studies with the ring were recently completed in Belgium.

Maraviroc
---------

Maraviroc, a CCR5 co-receptor antagonist marketed as Selzentry^®^(Pfizer Labs, New York, NY, USA) for treatment of CCR5-tropic HIV-1 infection, is in development as a vaginal microbicide \[[@B20]\]. Vaginal gels and rings containing a combination of dapivirine plus maraviroc are in development; phase I clinical trials are planned for 2011. These products have the potential advantage of blocking HIV infection at two different steps in the replication cycle, attachment and reverse transcription. Vaginal gels and rings containing maraviroc as a single agent are in development in parallel with the combination dosage forms and will be included in the phase I clinical trials planned for 2011. In addition, a combination vaginal film with maraviroc and tenofovir is in preclinical development.

MIV-150
-------

MIV-150 is an NNRTI with potent activity against HIV-1 and HIV-2, including free HIV-1 and HIV-1 strains that are resistant to other ARVs \[[@B21],[@B22]\]. MIV-150 is currently under development at Population Council in both microbicide gel (PC-815 and PC-1005) and ring formulations \[[@B23]-[@B25]\]. Population Council researchers are also developing vaginal rings that contain both MIV-150 and a contraceptive to protect women against both HIV infection and pregnancy.

Challenges Faced in Microbicide Development
===========================================

The establishment of surrogate markers for determination of clinical efficacy and survival-enhancing effects of ARVs (rises in CD4 cell counts and decreases in HIV viral load) dramatically enhanced the development of new medicines for the treatment of HIV infection \[[@B26],[@B27]\]. To date, no surrogate markers have been identified for measurement of the efficacy of HIV prevention tools; therefore, microbicide clinical trials are designed to measure the difference in infection rates between the active and control groups. For this reason, trial settings must have sufficiently high HIV incidence rates (typically over 2%) to show a significant reduction with the intervention. Furthermore, careful selection of microbicide candidates to test in clinical trials is imperative because of shared trial sites and high trial expenses. Because of the lack of surrogate markers, in vitro assays, cervical explant models, and animal models have been utilized to estimate the potential for preventive efficacy of new microbicide compounds in women. These models are experimental and have not been validated. The development of pharmacokinetic/pharmacodynamic models is being explored \[[@B28]\] and ideally would be able to predict the pharmacodynamic effect of a microbicide candidate from the pharmacokinetic profile.

Adherence with the microbicide regimen is generally measured in clinical trials by self-reported product use and counting of returned used and unused gel applicators \[[@B29]\]. this provides only an estimate of true adherence and no information on the time of product insertion. Others have explored \"daily monitored adherence\" and found that daily contact with trial participants can improve adherence to the microbicide regimen \[[@B30]\].

Use of ARV-based vaginal microbicides could potentially induce drug resistance in individuals who are unaware that they are HIV infected if subtherapeutic drug levels consistent with the selection of resistance in vivo are attained. Systemic drug exposure after vaginal dosing with NRTl-and NNRTI-based microbicides has been shown to be low \[[@B13],[@B14],[@B16]-[@B18],[@B31],[@B32]\], while concentrations in cervicovaginal fluids have been shown to be many logs greater than in vitro concentrations at which resistance mutations were noted \[[@B13]\]. Combination microbicides with two drugs that target different steps in the HIV replication cycle may reduce the potential for development of HIV resistance by increasing the barrier to infection \[[@B28],[@B33]\]. Furthermore, combination microbicides may help prevent the transmission of virus resistant to a specific drug via the mechanism of action of the other drug in the combination. Development of resistance is being studied in the clinical context through the implementation of seroconvertor protocols \[[@B12],[@B13]\]. The monitoring of microbicide users for HlV infection is therefore important, and recommended timetables for HIV testing are under development. Monthly HIV testing is generally used in microbicide trials; however, this schedule may not be feasible after product approval.

Priorities in Microbicide Development
=====================================

Now that proof-of-concept for an ARV-based vaginal microbicide has been established through the successful completion of the CAPRISA trial \[[@B12]\], interest in new HIV prevention tools has received a boost. It is now a priority to set-up the necessary confirmatory and supporting studies for the continued clinical development of tenofovir gel, which could then lead to the approval and launch of the first ARV-based microbicide. Other ARV-based microbicides that hold promise for increasing potency and addressing product adherence concerns need to be prioritized for development, including products ready for efficacy testing such as the dapivirine-containing vaginal ring.

Optimizing implementation programs and measuring the real-life public health impact will be further milestones. Establishment of a comprehensive post-approval drug safety surveillance system is important when microbicides are introduced into the markets in developing countries because there is no experience with the use of these products in regions under the jurisdiction of the FDA or EMA. Also, since these products will be used by otherwise healthy women, monitoring product safety is paramount. Further development of ARV-based microbicides (including drug combinations) with longer-acting formulations and in multiple dosage forms remains a priority to offer women choices, a strategy that has proven to be very successful in the field of contraception \[[@B34],[@B35]\].

Pre-Exposure Prophylaxis (PrEP)
===============================

In addition to HIV microbicide development, oral PrEP of HIV infection with ARV drugs approved for treatment of HIV and AIDS is currently under investigation \[[@B36]-[@B39]\]. The VOICE trial described above is one such trial. Other PrEP trials being conducted worldwide are shown in Table [2](#T2){ref-type="table"}. All but one of these trials is with oral tenofovir disoproxil fumarate and/or oral emtricitabine plus tenofovir disoproxil fumarate. Intramuscular injection of TMC278LA, an NNRTI for HIV prevention, is presently being tested in a phase I trial in the UK. The results of the first oral PrEP trials in women are expected in 2010 and 2011.

###### 

Pre-Exposure Prophylaxis Trials in Progress.

  Trial Name (Number)                  Phase    Description                             Location                                            Sponsor                 No. of Subjects   Population                                 Intervention(s)                                                                Results Expected
  ------------------------------------ -------- --------------------------------------- --------------------------------------------------- ----------------------- ----------------- ------------------------------------------ ------------------------------------------------------------------------------ --------------------
  FEM-PrEP                             III      Safety & effectiveness                  Kenya, South Africa, Tanzania, Zimbabwe             FHI, USAID, BMGF        3900              Heterosexual women                         Daily oral TDF/FTC                                                             Q3 2013
  iPrEs                                III      Safety & effectiveness                  Brazil, Ecuador, Peru, South Africa, Thailand, US   NIH, BMGF               2499              Men who have sex with men                  Daily oral TDF/FTC                                                             Q4 2010 \[[@B39]\]
  Partners PrEP                        III      Safety & effectiveness                  Kenya, Uganda                                       BMGF                    4700              Serodiscordant heterosexual couples        Daily oral TDF; daily oral TDF/FTC                                             Ql 2013
  Bangkok Tenofovir Study (CDC 4370)   II/III   Safety & effectiveness                  Thailand                                            CDC                     2400              Injection drug users                       Daily oral TDF                                                                 Ql 2012
  VOICE (MTN 003)                      IIB      Safety & effectiveness                  South Africa, Uganda, Zimbabwe                      MTN, NIH                5000              Heterosexual women                         Daily oral TDF; daily oral TDF/FTC; daily topical tenofovir gel                Ql 2013
  PrEP in YMSM (ATN 082)               II       Safety, acceptability, & feasibility    US                                                  ATN, NICHD              99                Young men who have sex with men            Daily oral TDF/FTC                                                             Q2 2011
  TDF2 (CDC 4940)                      II       Safety & adherence                      Botswana                                            CDC                     1200              Heterosexual men and women                 Daily oral TDF/FTC                                                             Q2 2011
  IAVI E001 & E002                     I/II     Safety, acceptability, & adherence      Kenya, Uganda                                       IAVI                    150               Serodiscordant couples and men and women   Daily oral TDF/FTC; intermittent oral TDF/FTC (twice weekly + coital dosing)   Q4 2010
  TMC278-TiDP15-C158\*                 I        Safety, tolerance & pharmaco-kinetics   UK                                                  Tibotec Pharmaceucals   100               Men and women                              TMC278LA injected IM                                                           Ql 2011

ATN = Adolescent Medicine Trials Network; BMGF = Bill & Melinda Gates Foundation; CDC = US Centers for Disease Control and Prevention; FHI = Family Health International;

FTC = emtricitabine; IAVI = International AIDS Vaccine Initiative; MTN = Microbicide Trials Network; NICHD = National Institute of Child Health & Human Development;

NIH = US National Institutes of Health; TDF = tenofovir disoproxil fumerate; USAID = United States Agency for International Development; YMSM = young men who have sex with men

Reference: <http://www.avac.org/ht/d/sp/a/GetDocumentAction/i/3113> (accessed december 1, 2010)

\*Reference: <http://www.clinicaltrials.gov/ct2/show/NCT01031589?term=tmc278la&rank=3> (accessed december 1, 2010)

The findings of these PrEP trials should hopefully demonstrate the efficacy, safety, and tolerability of ARVs in HIV-negative individuals. In addition, the results will be used to develop public health guidelines for prevention of HIV transmission in different populations such as heterosexual couples, serodiscordant couples, men who have sex with men, and injection drug users. If proven safe and effective, PrEP could help address the urgent need for a female-initiated prevention method for women worldwide.

Conclusions
===========

There is an immediate need for female-initiated HIV prevention tools. Microbicide research, like most HIV prevention research, has faced many hurdles over the past two decades, but proof-of-concept in the CAPRISA trial has reignited the hope of obtaining safe and effective HIV microbicides that are acceptable to the women who will use these products. Several ARV-based microbicides are in clinical trials at this time, and many others are in preclinical stages of development. Oral PrEP with ARVs approved for treatment of HIV/AIDS is currently under investigation with the first trial results expected in 2010 and 2011.
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